Sangui BioTech International Inc.

  • WKN: 906757
  • ISIN: US80105B1017
  • Land: Germany

Nachricht vom 12.02.2015 | 12:00

Sangui BioTech International Inc.: Revenues slightly improved in the first half of the 2015 financial year

Sangui BioTech International Inc. / Key word(s): Quarter Results

2015-02-12 / 12:00


Sangui BioTech: Revenues slightly improved in the first half of the 2015 financial year

Research and development focuses on preclinical trials

Witten, Germany, February 12, 2015

For the first half (as of December 31, 2014) of its 2015 financial year Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD104,906 an increase of 74.0% over the revenues in the first half of the financial year 2014. In the second quarter (October through December 2014) revenues amounted to USD31,166 a decrease of 57.7% as compared with the most recent quarter(July through September 2014).

Research and development expenses amounted to USD134,977 (H1/2014: USD 107,234). The increase is due to the ongoing preclinical trials aimed at demonstrating the functionality of Sangui's technology with respect to various indications. The net loss attributable to shareholders of the parent company came to USD355,928 (H1/2014: USD570,032), the cash outflow from operations during the six months amounted to USD318,740 (H1/2014: USD337,419).

As of December 31, 2014, the equity ratio was minus 33.3% (June 30, 2014: 2.8%).

In the course of the second quarter, preclinical trials at Giessen University demonstrated that a hemoglobin based product developed by SanguiBioTech is apt to improve the oxygen supply of vital organs. It is now being supposed that Sangui's hemoglobin-based artificial oxygen carriers may interrupt the self-perpetuating mechanism of septic shock, that has so far been highly resistant to treatment, and may thus ultimately reduce the high mortality rates.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace ( SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

2015-02-12 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

322423  2015-02-12 


EQS Group: Rating lautet Kaufen

Die Vorzeichen für die EQS Group AG sind positiv. Ein wesentlicher Umsatztreiber für das Jahr 2020 sollte die Migration von Bestandskunden vom COCKPIT in das COCKPIT 2.0 bedeuten. Darüber hinaus erwarten wir ein gutes Wachstum in den übrigen Bereichen, da die EQS mit vielen Produkten auch von der Coronakrise profitieren kann. So werden z. B. Online-Hauptversammlungen, Webcasts und Telefonkonferenzen vermehrt gebucht: Unseres Erachtens sollte es auch zu einer höhere Anzahl an Pflichtmeldungen von Unternehmen kommen. Unser Kursziel liegt bei 91,50 €, das Rating lautet weiter Kaufen.

News im Fokus

Linde Recognized as a Leader in Diversity & Inclusion by DiversityInc

22. Mai 2020, 11:59

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

20. Mai 2020